Skip to main content
< Back to news
Four experts of renowned international prestige -including Dr. Eliandre de Oliveira, head of the PCB's Proteomics Platform– will lead this B·Debate (Photo: Barcelona Science Park).

Dr. Eliandre de Oliveira, cientific leader of the B·Debate on clinical proteomics

World leaders in proteomics will meet at CaixaForum Barcelona on 7 and 8 November in an event held by B·Debate, an initiative by Biocat and Obra Social ‘la Caixa’, co-organized in this edition by Barcelona Science Park (PCB), ProteoRed-ISCIII, Bellvitge Biomedical Research Institute (IDIBELL), Centre for Genomic Regulation (CRG) and Vall d’Hebron Institute of Oncology (VHIO). Four experts of renowned prestige in this field –including Dr. Eliandre de Oliveira, head of the PCB's Proteomics Platform– will lead the debate.


This B·Debat, titled “Clinical Proteomics: towards personalized medicine and health“, aims to introduce new applications, developments and recent innovations of the proteomics field to the biomedical community, to empower clinicians and translational researchers with latest generation proteomics technologies for personalized medicine, and to promote enriching scientific discussions among academic and medical communities, biotechnology industry and local citizens to foster new collaborations and synergies.

The meeting will take place in two consecutive days with six different thematic sections, and it is designed to appeal biomedical and translational researchers at all stages of their scientific career, clinicians from the national health system, biotechnology and pharmaceutical industry scientists, and policy makers, scientific journalists and engaged citizens.

The impact of proteomics on the future personalized medicine

Proteomics provides functional information about the activity of proteins, which is often crucial for the understanding of cell physiology. During the last decade, the development of the field has facilitated the characterization of the main mechanisms of cell signaling, and the deciphering of protein-protein interaction that are essential in gene regulation and that govern the different phenotypes observed in cells and tissues. In addition, the consolidation of proteomics technologies have enabled new large-scope applications for clinical and biomedical research in which hundreds of samples can be analyzed by mass spectrometry.

These applications allow the identification and quantification of proteins in biological fluids, biopsies and animal models, as well as the analysis of post-translational modifications, interactions and intracellular localization of proteins, in order to find markers of disease, understand the pathological molecular mechanisms, and provide new treatments for patients.

► Registration and abstracts submission now open. More information is available on the B·Debate website [+]